-
Je něco špatně v tomto záznamu ?
Outcomes of the VictoTM adjustable artificial urinary sphincter in the treatment of male incontinence
J. Krhut, L. Bartáková, A. Kondé, RP. Sýkora, T. Rychlý, R. Zachoval
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
PubMed
39187277
DOI
10.1111/bju.16511
Knihovny.cz E-zdroje
- MeSH
- inkontinence moči * chirurgie terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- pooperační komplikace MeSH
- prospektivní studie MeSH
- prostatektomie * škodlivé účinky MeSH
- senioři MeSH
- spokojenost pacientů MeSH
- umělý močový svěrač * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: To report the clinical outcomes of the VictoTM (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. PATIENTS AND METHODS: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes. RESULTS: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period. CONCLUSION: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.
Department of Surgical Studies Ostrava University Ostrava Czech Republic
Department of Urology University Hospital Ostrava Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002936
- 003
- CZ-PrNML
- 005
- 20250206103947.0
- 007
- ta
- 008
- 250121s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bju.16511 $2 doi
- 035 __
- $a (PubMed)39187277
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krhut, Jan $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000342055926 $7 mzk2005309234
- 245 10
- $a Outcomes of the VictoTM adjustable artificial urinary sphincter in the treatment of male incontinence / $c J. Krhut, L. Bartáková, A. Kondé, RP. Sýkora, T. Rychlý, R. Zachoval
- 520 9_
- $a OBJECTIVES: To report the clinical outcomes of the VictoTM (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. PATIENTS AND METHODS: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes. RESULTS: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period. CONCLUSION: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a umělý močový svěrač $7 D016741
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a inkontinence moči $x chirurgie $x terapie $7 D014549
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a prostatektomie $x škodlivé účinky $7 D011468
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a spokojenost pacientů $7 D017060
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pooperační komplikace $7 D011183
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bartáková, Lucie $u Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czech Republic $1 https://orcid.org/0009000434390032
- 700 1_
- $a Kondé, Adéla $u Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB - Technical University, Ostrava, Czech Republic $u Department of the Deputy Director for Science, Research and Education, University Hospital, Ostrava, Czech Republic
- 700 1_
- $a Sýkora, Radek Paus $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic
- 700 1_
- $a Rychlý, Tomáš $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000219727870
- 700 1_
- $a Zachoval, Roman $u Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czech Republic
- 773 0_
- $w MED00011371 $t BJU international $x 1464-410X $g Roč. 135, č. 1 (2025), s. 103-109
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39187277 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103943 $b ABA008
- 999 __
- $a ok $b bmc $g 2262995 $s 1238943
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 135 $c 1 $d 103-109 $e 20240826 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
- LZP __
- $a Pubmed-20250121